Bacteroides fragilis strain ZY-312

Bacteroides fragilis strain ZY-312 is a live, non-pathogenic, anaerobic probiotic bacterial strain isolated from the feces of a healthy, breast-fed infant. It exhibits high resistance to bile and moderate resistance to acidic conditions, allowing it to survive in the gastrointestinal tract. The strain enhances macrophage phagocytic function, modulates inflammatory signaling, and polarizes macrophages toward the M1 phenotype by upregulating IL-12, IL-1β, and inducible nitric oxide synthase. As a probiotic, ZY-312 has demonstrated efficacy in animal models of necrotizing enterocolitis (NEC), radiation-induced intestinal injury, and colitis. Its mechanisms of action include direct suppression of pathogenic bacteria (Cronobacter sakazakii), modulation of the host immune response (notably via the IL-22/STAT3 pathway), promotion of intestinal epithelial cell proliferation, stem cell regeneration, goblet cell (mucus-secreting cell) generation, and maintenance of tight junction integrity. These properties highlight its therapeutic potential in gastrointestinal disorders and suggest possible clinical applications as a next-generation probiotic, particularly in intestinal inflammation and injury[1][2][3][4][5][6][7].

Other names

B. fragilis ZY-312